Testing effectiveness (Phase 2)WithdrawnNCT02263898
What this trial is testing
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
Who this might be right for
Recurrent MelanomaStage IV Melanoma
Jonsson Comprehensive Cancer Center